Bortezomib inhibits hepatocellular carcinoma via the Hippo‐Yes‐associated protein signalling pathway
Basic & Clinical Pharmacology & Toxicology · 2023-04 · 132 (4) · 297-311
DOI: 10.1111/bcpt.13832 ↗Kurz gefasst
Fachartikel in der Zeitschrift Basic & Clinical Pharmacology & Toxicology, online erschienen am 15.01.2023. Verfasst von Yu Liao und 7 weiteren Autor:innen. Beteiligte Einrichtung: College of Life Sciences, Nanjing Normal University, Nanjing, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) is one of the principle causes of cancer‐associated death throughout the world. However, the patients with HCC are insensitive to traditional drugs and lack effective therapeutic drugs. Dysregulation of Hippo‐Yes‐associated protein (YAP) signalling is closely associated with HCC. Bortezomib (BTZ) is mainly used in clinical multiple myeloma. It has recently been confirmed that BTZ could suppress cell proliferation in many different types of cancer. Nevertheless, the precise effects of BTZ on HCC and its possible interactions with the Hippo‐YAP signalling pathway in HCC cells remain largely unknown. In this study, HCC cell lines (HepG2 and Huh7) and nude mice with xenograft tumours were used to evaluate the influences of BTZ. Furthermore, we focused on exploring whether BTZ exerts its anti‐HCC effect through the Hippo‐YAP signalling pathway and aimed to lay a theoretical foundation for BTZ as a potential therapeutic drug for HCC. Herein, our results disclose a new mechanism of BTZ in controlling the cell growth of HCC. BTZ downregulates the level of YAP by promoting LATS1 expression to inhibit the growth of HCC cells, which leads to the phosphorylation of YAP and limits YAP nuclear translocation. In sum, our data confirmed that the Hippo‐YAP signalling pathway mediates the anti‐HCC effects of BTZ.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Life Sciences, Nanjing Normal University, Nanjing, China.
- School of Food Science and Pharmaceutical Engineering, Nanjing Normal University, Nanjing, China.
ORCID-Profile: Guanglin Xu
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Liao, Y., Hu, K., Liu, W., Wang, W., Qiu, H., Pan, S., Lv, Q., & Xu, G. (2023). Bortezomib inhibits hepatocellular carcinoma via the Hippo‐Yes‐associated protein signalling pathway. Basic & Clinical Pharmacology & Toxicology, 132(4), 297-311. https://doi.org/10.1111/bcpt.13832
Vancouver
Liao Y, Hu K, Liu W, Wang W, Qiu H, Pan S, et al. Bortezomib inhibits hepatocellular carcinoma via the Hippo‐Yes‐associated protein signalling pathway. Basic & Clinical Pharmacology & Toxicology. 2023;132(4):297-311. doi:10.1111/bcpt.13832
BibTeX
@article{Liao2023,
author = {Liao, Yu and Hu, Kejun and Liu, Wangwang and Wang, Wei and Qiu, Huanhuan and Pan, Shumin and Lv, Qi and Xu, Guanglin},
title = {Bortezomib inhibits hepatocellular carcinoma via the Hippo‐Yes‐associated protein signalling pathway},
journal = {Basic & Clinical Pharmacology & Toxicology},
year = {2023},
volume = {132},
number = {4},
pages = {297--311},
doi = {10.1111/bcpt.13832}
}
EUVIMED